Free Trial

Supernus Pharmaceuticals (SUPN) News Today

→ No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (From Hedgeye) (Ad)
Free SUPN Stock Alerts
$26.26
-0.89 (-3.28%)
(As of 06/7/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 8 at 10:37 AM | marketbeat.com
Epoch Investment Partners Inc. Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Epoch Investment Partners Inc. reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 10.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 346,336 shares of the special
June 7 at 4:07 AM | marketbeat.com
Norges Bank Takes $7.96 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Norges Bank acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 275,140 shares of the specialty pharmaceu
June 5 at 11:53 AM | marketbeat.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is Armistice Capital LLC's 3rd Largest Position
Armistice Capital LLC lessened its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 8.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,650,000 shares of the specialty pharmaceutical company's stoc
June 3, 2024 | marketbeat.com
Stephens Investment Management Group LLC Increases Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Stephens Investment Management Group LLC raised its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 11.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,904,864 shares of the specialty
June 1, 2024 | marketbeat.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Axiom Investors LLC DE
Axiom Investors LLC DE boosted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 255.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 48,455 shares of the specialty pharmaceutical
May 30, 2024 | globenewswire.com
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 26, 2024 | marketbeat.com
Congress Wealth Management LLC DE Cuts Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Congress Wealth Management LLC DE trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 18.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 129,051 shares of the specialty pharmace
May 24, 2024 | finanznachrichten.de
Supernus Pharmaceuticals, Inc.: Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
May 24, 2024 | finance.yahoo.com
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
May 23, 2024 | globenewswire.com
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
May 23, 2024 | prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
May 21, 2024 | marketbeat.com
GW&K Investment Management LLC Decreases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
GW&K Investment Management LLC cut its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 6.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,317,526 shares of the specialty pharmaceutic
May 16, 2024 | prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
May 16, 2024 | marketbeat.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Sees Unusually-High Trading Volume
Supernus Pharmaceuticals (NASDAQ:SUPN) Sees Strong Trading Volume
May 10, 2024 | finance.yahoo.com
Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)
May 10, 2024 | finance.yahoo.com
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
May 9, 2024 | globenewswire.com
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
May 9, 2024 | finance.yahoo.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
May 9, 2024 | finance.yahoo.com
Supernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
May 8, 2024 | investorplace.com
SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024
May 8, 2024 | globenewswire.com
Supernus Announces First Quarter 2024 Financial Results
May 7, 2024 | markets.businessinsider.com
Supernus's ADHD Drug Qelbree To Be Commercialized In Latin America By M8 Pharma
May 7, 2024 | prnewswire.com
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America
May 6, 2024 | prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
May 2, 2024 | businesswire.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
May 1, 2024 | businesswire.com
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
May 1, 2024 | globenewswire.com
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
May 1, 2024 | marketbeat.com
Supernus Pharmaceuticals (SUPN) Scheduled to Post Quarterly Earnings on Wednesday
Supernus Pharmaceuticals (NASDAQ:SUPN) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=589006)
April 29, 2024 | businesswire.com
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
April 28, 2024 | prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
April 27, 2024 | marketbeat.com
Louisiana State Employees Retirement System Purchases New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Louisiana State Employees Retirement System purchased a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 27,300 shares of the specialty
April 24, 2024 | globenewswire.com
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
April 20, 2024 | prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
April 20, 2024 | stockhouse.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
April 19, 2024 | nasdaq.com
Notable Two Hundred Day Moving Average Cross - SUPN
April 15, 2024 | markets.businessinsider.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)
April 15, 2024 | marketbeat.com
Phocas Financial Corp. Sells 35,507 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Phocas Financial Corp. lessened its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 22.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 121,559 shares of the specialty pharmaceutical company's
April 10, 2024 | uk.investing.com
Supernus receives FDA rejection for Parkinson's treatment, submits additional data
April 9, 2024 | yahoo.com
US FDA declines to approve Supernus' Parkinson's combination again (April 8)
April 8, 2024 | finanznachrichten.de
Supernus Pharmaceuticals, Inc.: Supernus Provides Regulatory Update for SPN-830
April 8, 2024 | msn.com
Supernus stock slides as FDA rejects Parkinson's disease infusion device
April 8, 2024 | finance.yahoo.com
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
April 8, 2024 | marketbeat.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down to $33.55
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down to $33.55
April 8, 2024 | reuters.com
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease
April 8, 2024 | globenewswire.com
Supernus Provides Regulatory Update for SPN-830
April 6, 2024 | marketbeat.com
Assenagon Asset Management S.A. Buys New Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Assenagon Asset Management S.A. purchased a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 36,254 shares of the
March 26, 2024 | insidertrades.com
Padmanabh P. Bhatt Sells 14,491 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock
March 25, 2024 | marketbeat.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Price Down 3.9% Following Insider Selling
Supernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 3.9% After Insider Selling
March 25, 2024 | marketbeat.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells $511,677.21 in Stock
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) VP Padmanabh P. Bhatt sold 14,491 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $35.31, for a total value of $511,677.21. Following the transaction, the vice president now owns 8,570 shares in the company, valued at $302,606.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
March 22, 2024 | insidertrades.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 12,364 Shares
Get Supernus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

A Wave of Creative Destruction Set to Strike June 30 (Ad)

You have until June 30 … then all hell will begin to break loose… The White House and Goldman Sachs predict generative AI will soon replace up to 300 MILLION jobs — one in every four careers … worldwide.

Click here for details. 

SUPN Media Mentions By Week

SUPN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SUPN
News Sentiment
▼
1.60

0.72
▲
Average
Medical
News Sentiment

SUPN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SUPN Articles
This Week
▼
4

3
▲
SUPN Articles
Average Week

Get Supernus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:SUPN) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners
Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...
Colonial Metals | Sponsored
Warren Buffett & 48 Members of Congress Are Buying ONE Sector…
Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...
InvestorPlace | Sponsored
The new masters of energy
According to one source, this new grid could soon provide energy to “one billion people in the world who don’t...
Porter & Company | Sponsored
We’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)
Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from the...
Paradigm Press | Sponsored
Breaking - The US Gov. Seized CITGO
Do you want an investment that can double or triple your money in the next three months? The US Court is cu...
Augury Research | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored